We conducted a prospective, randomized, double-blind study comparing amphotericin B colloidal dispersion (ABCD) with amphotericin B in the empirical treatment of fever and neutropenia. Patients with neutropenia and unresolved fever after §3 days of empirical antibiotic therapy were stratified by age and concomitant use of cyclosporine or tacrolimus. Patients were then randomized to receive therapy with ABCD (4 mg/[kgrd]) or amphotericin B (0.8 mg/[kgrd]) for £14 days. A total of 213 patients were enrolled, of whom 196 were evaluable for efficacy. Fifty percent of ABCDtreated patients and 43.2% of amphotericin B -treated patients had a therapeutic response (P Å .31). Renal dysfunction was less likely to develop and occurred later in ABCD recipients than in amphotericin B recipients (P õ .001 for both parameters). Infusion-related hypoxia and chills were more common in ABCD recipients than in amphotericin B recipients (P Å .013 and P Å .018, respectively). ABCD appeared comparable in efficacy with amphotericin B, and renal dysfunction associated with ABCD was significantly less than that associated with amphotericin B. However, infusion-related events were more common with ABCD treatment than with amphotericin B treatment.
Empirical antimicrobial therapy for patients with chemothercin B -induced nephrotoxicity may be exacerbated by concomitant use of nephrotoxic agents. apy-induced neutropenia and fever has become standard pracConcerns about renal toxicity associated with amphotericin tice [1] . In particular, pivotal studies [2, 3] established the B may preclude empirical initiation and maximal dosing of addition of amphotericin B as an important therapeutic interamphotericin B therapy for the neutropenic, febrile patient. vention for patients with persistent fever and neutropenia that Current intensive chemotherapy and marrow transplant regidid not resolve following 4 to 7 days of empirical antibacterial mens and consequent prolonged episodes of neutropenia fretherapy. However, the administration of amphotericin B is assoquently lead to sustained exposures to nephrotoxic agents, such ciated with infusion-related and renal toxicity, and amphoterias aminoglycosides. In addition, cyclosporine use in cases of allogeneic bone marrow transplantation independently predisposes to renal dysfunction. Reluctance to use amphotericin B Received 5 January 1998; revised 18 March 1998. in these settings may result in worse outcomes, although this
This work was presented in part at the American Society of Hematology finding has not been demonstrated in clinical trials.
meeting held on 6 -10 December 1996 in Orlando, Florida.
Lipid-associated formulations of amphotericin B were develInformed consent was obtained from the patients or their parents or guardians, and the guidelines for human experimentation of the U.S. Department of oped to enhance the therapeutic index of the parent compound Health and Human Services and those of the authors' institutions were followed while maintaining its antifungal activity. Amphotericin B col- by the National Cancer Institute (CA 18029) and the National Heart Lung Results of preclinical [4] , uncontrolled [5] , and retrospective, Blood Institute (HL 36444). This work was supported by SEQUUS Pharmaceucontrolled clinical trials [6] established in prospective, controlled clinical trials.
Materials and Methods
Patients received the study drug until an end point was reached: an absolute neutrophil count of ú500/mm 3 for 48
Eligibility Criteria
hours, identification of an infection thought to be the cause of fever, toxicity leading to study drug discontinuation, or a Patients were eligible for the study if they were neutropenic maximum of 14 days of therapy. Exceptions to study drug following chemotherapy for hematologic malignancy or had discontinuation because of recovery of neutrophil count were undergone marrow or stem cell transplantation in the previous made at institutions where empirical amphotericin B therapy 3 months. Patients were anticipated to be neutropenic (absolute is discontinued when absolute neutrophil counts are ú1,000/mm 3 neutrophil count, £500/mm 3 or £1,000/mm 3 and expected to or where stable, afebrile pediatric patients with absolute neutrodecline to £500/mm 3 within 2 days) for §7 days. Fever was phil counts of §200/mm 3 are routinely discharged. After study defined as continued temperatures of §38ЊC following at least drug discontinuation, patients could receive continued antifun-72 hours of empirical broad-spectrum antibacterial therapy or gal therapy at the discretion of their physician. recrudescent fever (temperature to §38ЊC) on two or more Complete physical examinations and the following laboraoccasions after initial defervescence with antibacterial treattory evaluations were performed at baseline, every 3 days durment. The choice of §3 days of fever and neutropenia reflected ing study drug therapy, and at the end of the study: determinaclinical practice at the participating institutions.
tion of complete blood cell count and serum electrolyte levels, Patients were excluded from the study because of the followliver and renal function tests, blood cultures, and urinalysis with ing reasons: prior anaphylactoid reaction to amphotericin B microscopic examination. Other cultures, radiographic studies, products, amphotericin B therapy in the 2 weeks before the and aspiration or biopsy of suspicious lesions were performed current fever, documented systemic fungal infection within 1 as clinically indicated. month of study enrollment, or a physician's unwillingness to All patients were required to have a follow-up evaluation discontinue other systemic antifungal therapy. Patients were for detection of suspected or documented fungal infection 7 also excluded because of renal impairment (serum creatinine days after the last dose of the study drug. Patients who received level three or more times the upper limit of normal), hepatic at least seven doses of the study drug and/or discontinued study impairment (serum aspartate aminotransferase or alanine amidrug therapy because of an adverse event underwent follow-up notransferase level, §4.0 mkat/L [240 U/L]; alkaline phosphaevaluations 2, 3, and 4 weeks after study drug discontinuation. tase level, §11.50 mkat/L [690 U/L]; and/or total bilirubin Survival was followed up through 4 weeks after the last dose level, §6.0 mg/dL), life expectancy of õ14 days, prior particiof the study drug. pation in the study, and use of macrophage colony-stimulating factor or granulocyte transfusions.
Drug Administration
All participating centers had institutional review board apAfter randomization, patients received a 10-mL test dose of proval of the protocol. Written informed consent was obtained the study drug (4 mg of ABCD or 0.8 mg of amphotericin B) from all patients or from the parent or legal guardian of minors.
that was administered from a prepared solution over 15 -20 minutes. If this dose was tolerated, the patient received premedications (acetaminophen and diphenhydramine) before re-
Study Design
ceiving the first therapeutic dose over 4 hours. Infusion-related This was a randomized, double-blind multicenter trial. At chills and fever were treated symptomatically. If infusion-reenrollment, patients were grouped by age and concurrent use lated toxicity occurred, hydrocortisone and meperidine could of cyclosporine or tacrolimus: group 1 (adults [16 years of age be added to subsequent premedication regimens. Therapy could or older] receiving the agents), group 2 (adults not receiving be discontinued because of severe or recurrent infusion-related the agents), group 3 (children [2 years of age or older and reactions. younger than 16 years of age] receiving the agents), and group Study drug administration was interrupted because of any 4 (children not receiving the agents). At each center and within moderately severe toxicity attributable to the study drug. Treateach of these groups, patients were randomized equally to rement was resumed if the degree of toxicity lessened, but if ceive either 4.0 mg of intravenous ABCD/(kgrd) (Amphotec toxicity persisted or recurred, study drug therapy was discon-[amphotericin B cholesteryl sulfate complex]; SEQUUS Phartinued. Therapy was discontinued because of any severe toxicmaceuticals, Menlo Park, CA) or 0.8 mg of intravenous amphoity possibly or probably caused by the study drug. At the investericin B/(kgrd) (Fungizone; Bristol-Myers Squibb, Princeton, tigator's discretion, therapy could also be discontinued because NJ). Each study site and enrollment group had its own randomof an increase in the serum creatinine level to §133 mmol/L ization table. At enrollment, investigators contacted the sponsor ( §1.5 mg/dL) or a doubling of the level from baseline. (SEQUUS Pharmaceuticals) with the eligibility information
Efficacy Evaluation
and group designation; the site pharmacist was then given the randomization assignment. Blinding was simplified by the simiEligible patients who received no concomitant systemic antifungal therapy, received at least 7 days of the study drug, lar clear yellow appearance of the study drugs.
/ 9c52$$au40
07-10-98 15:12:01 cida UC: CID and/or reached a study end point at any time during study drug ABCD recipients and nine amphotericin B recipients) were not evaluable because of study drug discontinuation before administration were evaluable for efficacy.
A successful treatment outcome included all of the following reaching a study end point or because of receipt of concomitant systemic antifungal therapy. Six children younger than the age criteria: survival for §7 days after the last dose of the study drug, lack of suspected or documented fungal infection during of 2 were enrolled as protocol exceptions. Demographic and baseline characteristics of evaluable pathe study and within 7 days of the last dose of the study drug, lack of study drug discontinuation because of adverse events, tients are outlined in table 1. There were no significant differences in baseline parameters between the two treatment arms, and lack of fever on the day of discontinuation of therapy. Fever (temperature, §38.0ЊC) that occurred during or within controlling for enrollment group. For groups 1 and 3, the median baseline cyclosporine dose was 2.86 mg/kg (range, 0.60 -2 hours of study drug or blood product administration was considered infusion-or transfusion-related. Defervescence was 11.34 mg/kg) for ABCD recipients and 2.87 mg/kg (range, 0.61 -20.16 mg/kg) for amphotericin B recipients. Only four defined as an absence of fever for 48 hours. Sustained defervescence was defined as an absence of fever for 48 hours with patients received tacrolimus therapy. The median daily dose of amphotericin B was 4.0 mg/kg no recurrence before the end of study drug administration. Documented fungal infections were defined as described prefor ABCD recipients and 0.8 mg/kg for amphotericin B recipients. The median cumulative dose for ABCD recipients viously [5, 7] , but the determination of suspected fungal infections was left to the discretion of the investigator.
(1,884 mg) was approximately fivefold greater than that for amphotericin B recipients (380 mg). The median duration of
Safety Evaluation
treatment for all patients who received study drug was 8.0 days (9.0 days for ABCD recipients and 7.5 days for amphotericin All patients who received any amount of the study drug were B recipients). evaluated for safety. Renal toxicity was defined as any of the following: a doubling in the serum creatinine level from baseline, an increase of 88 mmol/L (1.0 mg/dL) in the serum creatiTreatment Outcome nine level from baseline, or a §50% decrease in the calculated Follow-up information for three ABCD recipients was increatinine clearance from baseline during study drug adminiscomplete; therefore, 193 patients were evaluable for response tration. Patients for whom therapy was prematurely discon- (table 2) . A successful response was noted in 49 (50%) of 98 tinued and who did not experience renal toxicity before discon-ABCD recipients and in 41 (43.2%) of 95 amphotericin B tinuation were classified as having no renal toxicity.
recipients (P Å .31, controlling for enrollment group). The 95% confidence interval for treatment difference was 07.2 to
Statistical Analysis
20.9, where the lower bound was within 010%. The rates of The sample size determination was based on the incidence successful outcome associated with ABCD and amphotericin of renal toxicity in the adult enrollment groups. It was estimated B in each enrollment group were comparable (data not shown). that 50% of patients receiving amphotericin B therapy would There was also no significant difference between treatment experience renal toxicity. Therefore, 60 evaluable patients in groups in the percentage of patients who had defervescence, the each enrollment group (30 per treatment arm), with an 80% median number of days to defervescence, and the occurrence of power and a two-sided P value of .05, would detect a decrease sustained defervescence. In addition, there were no significant of 35% in the occurrence of renal toxicity in ABCD recipients. differences in the percentage of patients who became afebrile Enrollment to the study was to be stopped once 120 evaluable by days 7 and 14 or in the percentage who had sustained adult patients (the population more likely to develop renal defervescence on those days (data not shown). toxicity) completed the trial.
Of all patients who received treatment, 32 (15 ABCD recipiTreatment differences were tested by using the Cochranents and 17 amphotericin B recipients) had suspected or docuMantel-Haenszel test [8] after controlling for enrollment group.
mented invasive fungal infection during study drug administraTime-to-event data were analyzed by means of stratified logtion or within 7 days of the end of treatment. Fourteen (14.3%) rank tests (stratified by enrollment group). In addition, twoof 98 evaluable ABCD recipients had suspected or documented sided 95% confidence intervals for treatment difference in profungal infection. Three infections were documented: in each portions of successful outcome, defervescence, and sustained case, blood or catheter tip cultures were positive for Candida defervescence were constructed. All statistical tests were twospecies from 1 to 4 days after the last dose of ABCD. Eleven sided.
patients were considered to have suspected fungal infection because of an abnormal finding on a chest radiograph. NOTE. Two AmB recipients had missing ANCs and WBC values at baseline and are not included. Of the remaining 194 patients, 101 had a missing ANC at baseline; therefore, their WBC count was used. Abbreviations: ABCD Å amphotericin B colloidal dispersion; AmB Å amphotericin B; ANC Å absolute neutrophil count; BMT Å bone marrow transplant; CMH Å Cochran-Mantel-Haenszel; group 1 Å adults receiving cyclosporine or tacrolimus; group 2 Å adults not receiving cyclosporine or tacrolimus; group 3 Å children receiving cyclosporine or tacrolimus; group 4 Å children not receiving cyclosporine or tacrolimus; NA Å not applicable or not available; PBSC Å peripheral blood stem cell transplant.
* CMH general association test, controlling for enrollment group. † CMH row mean scores test, controlling for enrollment group.
noted upon biopsy of skin lesions in one case, esophageal and ment arms in the incidence of fungal infection, controlling for enrollment group (data not shown). colonic lesions associated with fungal forms were found in one, and Aspergillus flavus was isolated from a biopsy speciEighty-four patients (42 ABCD recipients and 42 amphoterimen from a skin lesion adjacent to an indwelling catheter in cin B recipients) prematurely discontinued study drug therapy one. Eleven patients had radiologically suspected pulmonary because of the following reasons: nonfungal cause of fever (3 fungal infection.
ABCD recipients and 2 amphotericin B recipients), suspected or documented fungal infection (12 ABCD recipients and 12 Of the 28 evaluable patients with suspected or documented fungal infection, 11 of 14 ABCD recipients and eight of 14 amphotericin B recipients), adverse events (18 ABCD recipients and 20 amphotericin B recipients), other infection as cause amphotericin B recipients had undergone bone marrow transplantation. There were no significant differences between treatof fever at baseline (4 ABCD recipients and 5 amphotericin B / 9c52$$au40 07-10-98 15:12:01 cida UC: CID ABCD recipients had significantly less renal toxicity than NOTE. Only evaluable patients for whom all data were available are included. Patients who prematurely discontinued therapy and had not had deferdid amphotericin B recipients whether they were being treated vescence before the end of study participation were considered febrile. Unless with cyclosporine and aminoglycosides, aminoglycosides stated otherwise, data are no. of patients with response/total no. (%). Abbreviaalone, cyclosporine alone, or neither of these concomitant medtions: ABCD Å amphotericin B colloidal dispersion; AmB Å amphotericin B.
* Cochran-Mantel-Haenszel general association test, controlling for enrollications at baseline (P õ .001; data not shown).
ment group.
The absolute and percentage decline (P Å .012 and † Documented or suspected during study drug administration or within 7 P Å .005, respectively) in the serum potassium level from days of study drug discontinuation. ‡ Fisher's exact test.
baseline to the end of therapy was greater for amphotericin B § Logrank test, stratified by enrollment group.
recipients than for ABCD recipients, controlling for enrollment group. In addition, the absolute and percentage change in the serum potassium level from baseline to the end of treatment recipients), death (2 amphotericin B recipients), or administrawas less for ABCD recipients (P Å .008 and P Å .005, respective reasons unrelated to study drug safety or efficacy (5 ABCD tively) than for amphotericin B recipients, regardless of recipients and 1 amphotericin B recipient) (P Å .61 for associacyclosporine and/or aminoglycoside use at baseline (data not tion between treatment arm and discontinuation reason).
shown). There were no significant differences in changes in levels Safety Evaluation of serum magnesium (P Å .068, with less of a decline for All patients for whom a baseline serum creatinine level and ABCD recipients), aspartate aminotransferase, alkaline phosphatase, or serum bilirubin between ABCD recipients and ama subsequent value were available were evaluable for renal Table 3 . Summary of data on renal safety in a trial comparing ABCD and AmB as empirical treatment for neutropenia and fever. Table includes only those patients who received any amount of study drug for whom both a baseline serum creatinine level and at least one subsequent value were obtained. ABCD Å amphotericin B colloidal dispersion; AmB Å amphotericin B; EOT Å end of therapy; NA Å median not achieved.
* Cochran-Mantel-Haenszel general association test, controlling for enrollment group.
/ 9c52$$au40 07-10-98 15:12:01 cida UC: CID photericin B recipients. However, the percentage increase in photericin B in the empirical treatment of patients with neutropenic fever. Renal toxicity associated with ABCD was the alanine aminotransferase level from baseline to the end of treatment (P Å .006) was greater for ABCD recipients than significantly less frequent than that associated with amphotericin B for both adults and children, but infusion-related reactions for amphotericin B recipients.
All but one of the 213 enrolled patients received at least one and hypoxic events were more common in ABCD recipients than in amphotericin B recipients. dose of premedications before study drug administration. Premedications were used more frequently by ABCD recipients than This study was designed as a pilot trial of renal safety for neutropenic patients and does not address the incidence of by amphotericin B recipients. For example, in group 1, the mean duration of premedication use for ABCD recipients was 6.7 days fungal infection as a primary end point. Because current practice dictates that amphotericin B be included in empirical antiand it was 6.1 days for amphotericin B recipients. The P value for treatment difference for the entire population (controlling for fungal therapy, trials such as the current one would require many hundreds of patients to detect modest differences in the enrollment group) in the duration of premedication use was .068.
Most patients reported one or more adverse events possibly or relatively low incidence of predicted fungal infections [2, 3] . However, the rates of suspected or documented fungal infecprobably related to the study drug (99% of ABCD recipients and 92% of amphotericin B recipients, P Å .014). All adverse events tions, defervescence, and overall therapeutic response in the two treatment arms of this trial were similar. It is likely that reported by §10% of subjects in either treatment arm were analyzed. Chills were noted in 87 (79.8%) of 109 ABCD recipients ABCD has an efficacy similar to that of amphotericin B in the empirical antifungal treatment of patients with fever and and in 68 (65.4%) of 104 amphotericin B recipients (P Å .018).
Twenty-nine patients had adverse events classified as hypoxia neutropenia, but this finding cannot be stated definitively. This study provides convincing evidence that the renal safety during the study. Sixteen patients (13 ABCD recipients [one of whom was a child] and three amphotericin B patients, P Å .013) profile of ABCD is better than that of amphotericin B. The availability of an effective agent with the broad-spectrum antireported hypoxic events that were possibly or probably related to the study drug. Of these patients, 12 ABCD recipients had fungal activity of amphotericin B in a form that can be given with better renal safety has implications for the management documented oxygen saturation of õ90%, as did all three of the amphotericin B recipients. Most hypoxic episodes (11 ABCD of fever and neutropenia. Currently, the initiation of empirical amphotericin B treatment may be delayed for patients with recipients and all three amphotericin B recipients) were temporally associated with rigors and fever and required treatment with supmild to moderate renal insufficiency, and frequent adjustments in amphotericin B dose or schedule for patients with evolving plemental oxygen and other medications. All episodes resolved, but one amphotericin B recipient and five ABCD recipients were or existing renal insufficiency may impair antifungal efficacy, as well as that of aminoglycosides, cyclosporine, and other withdrawn from the study as a result of these events.
Adjustment in cyclosporine dose during study drug administramedications. These management problems may be ameliorated with a less nephrotoxic agent like ABCD. tion was assessed for groups 1 and 3. In group 1, the cyclosporine dose was adjusted for 16 (38%) of 42 ABCD recipients and for
In theory, stable renal function during the preengraftment period of bone marrow transplantation should lead to fewer adjustments 14 (33%) of 43 amphotericin B recipients; in group 3, adjustments in cyclosporine dose were made for seven (88%) of eight ABCD in cyclosporine dose and to a reduction in the incidence and/or grade of GVHD at a later time. However, analysis of these varirecipients and for five (71%) of seven amphotericin B recipients (P Å .45, controlling for enrollment group). There were also no ables did not reveal a difference in the occurrence of GVHD between the two treatment arms, despite significantly reduced significant differences in the frequency with which cyclosporine doses were changed for patients at risk for graft-vs.-host disease renal dysfunction associated with ABCD administration. The incidence of infusion-related chills and respiratory dis-(GVHD) [9] or in the worsening of the GVHD grade (from baseline to 28 days after study assessment) between the two tress associated with ABCD was greater than that associated with amphotericin B. Review of the hypoxia episodes revealed treatment arms (data not shown).
Mortality was assessed from the first dose through 28 days a strong correlation with typical infusion-related reactions to amphotericin B, such as fever and chills or rigors. Although after the last dose of the study drug. Twenty-nine patients died (16 ABCD recipients and 13 amphotericin B recipients); most most patients (63%) with hypoxic episodes had coexisting pulmonary abnormalities, no clear predictor of respiratory distress (59%) died §7 days after the last dose of the study drug. Two patients (one ABCD recipient and one amphotericin B due to ABCD or amphotericin B could be discerned. Respiratory distress characterized by wheezing and shortness recipient) died due to documented fungal infection. The death of one patient (an amphotericin B recipient with hypokalemia of breath is a known complication of amphotericin B infusions. The increased incidence among ABCD recipients may reflect the who died of arrhythmia) was possibly related to the study drug.
fivefold higher dose of amphotericin B that was given to patients Discussion randomized to receive ABCD therapy. A trial administering 2 mg of ABCD/(kgrd) (one-half the dose used in this trial) is underThis double-blind, comparative trial demonstrated no significant difference in therapeutic response to ABCD and amway to examine this question further. However, dose may not be / 9c52$$au40 07-10-98 15:12:01 cida UC: CID
